全文获取类型
收费全文 | 5165篇 |
免费 | 220篇 |
国内免费 | 170篇 |
专业分类
耳鼻咽喉 | 16篇 |
儿科学 | 210篇 |
妇产科学 | 665篇 |
基础医学 | 409篇 |
口腔科学 | 61篇 |
临床医学 | 798篇 |
内科学 | 989篇 |
皮肤病学 | 59篇 |
神经病学 | 189篇 |
特种医学 | 109篇 |
外科学 | 368篇 |
综合类 | 532篇 |
预防医学 | 339篇 |
眼科学 | 83篇 |
药学 | 310篇 |
中国医学 | 108篇 |
肿瘤学 | 310篇 |
出版年
2023年 | 31篇 |
2022年 | 43篇 |
2021年 | 47篇 |
2020年 | 44篇 |
2019年 | 26篇 |
2018年 | 63篇 |
2017年 | 46篇 |
2016年 | 55篇 |
2015年 | 56篇 |
2014年 | 56篇 |
2013年 | 94篇 |
2012年 | 251篇 |
2011年 | 465篇 |
2010年 | 165篇 |
2009年 | 133篇 |
2008年 | 281篇 |
2007年 | 285篇 |
2006年 | 239篇 |
2005年 | 253篇 |
2004年 | 384篇 |
2003年 | 406篇 |
2002年 | 298篇 |
2001年 | 227篇 |
2000年 | 97篇 |
1999年 | 177篇 |
1998年 | 155篇 |
1997年 | 170篇 |
1996年 | 115篇 |
1995年 | 91篇 |
1994年 | 82篇 |
1993年 | 83篇 |
1992年 | 83篇 |
1991年 | 71篇 |
1990年 | 48篇 |
1989年 | 53篇 |
1988年 | 34篇 |
1987年 | 27篇 |
1986年 | 20篇 |
1985年 | 20篇 |
1984年 | 24篇 |
1983年 | 25篇 |
1982年 | 22篇 |
1981年 | 25篇 |
1980年 | 21篇 |
1979年 | 25篇 |
1978年 | 16篇 |
1977年 | 13篇 |
1975年 | 21篇 |
1974年 | 11篇 |
1973年 | 17篇 |
排序方式: 共有5555条查询结果,搜索用时 15 毫秒
31.
Stark AR Carlo WA Tyson JE Papile LA Wright LL Shankaran S Donovan EF Oh W Bauer CR Saha S Poole WK Stoll BJ;National Institute of Child Health Human Development Neonatal Research Network 《The New England journal of medicine》2001,344(2):95-101
BACKGROUND: Early administration of high doses of dexamethasone may reduce the risk of chronic lung disease in premature infants but can cause complications. Whether moderate doses would be as effective but safer is not known. METHODS: We randomly assigned 220 infants with a birth weight of 501 to 1000 g who were treated with mechanical ventilation within 12 hours after birth to receive dexamethasone or placebo with either routine ventilatory support or permissive hypercapnia. The dexamethasone was administered within 24 hours after birth at a dose of 0.15 mg per kilogram of body weight per day for three days, followed by a tapering of the dose over a period of seven days. The primary outcome was death or chronic lung disease at 36 weeks' postmenstrual age. RESULTS: The relative risk of death or chronic lung disease in the dexamethasone-treated infants, as compared with those who received placebo, was 0.9 (95 percent confidence interval, 0.8 to 1.1). Since the effect of dexamethasone treatment did not vary according to the ventilatory approach, the two dexamethasone groups and the two placebo groups were combined. The infants in the dexamethasone group were less likely than those in the placebo group to be receiving oxygen supplementation 28 days after birth (P=0.004) or open-label dexamethasone (P=0.01), were more likely to have hypertension (P<0.001), and were more likely to be receiving insulin treatment for hyperglycemia (P=0.02). During the first 14 days, spontaneous gastrointestinal perforation occurred in a larger proportion of infants in the dexamethasone group (13 percent, vs. 4 percent in the placebo group; P=0.02). The dexamethasone-treated infants had a lower weight (P=0.02) and a smaller head circumference (P=0.04) at 36 weeks' postmenstrual age. CONCLUSIONS: In preterm infants, early administration of dexamethasone at a moderate dose has no effect on death or chronic lung disease and is associated with gastrointestinal perforation and decreased growth. 相似文献
32.
人巨细胞病毒UL136基因在临床低传代分离株中多态性分析 总被引:3,自引:1,他引:3
目的 研究人巨细胞病毒(human cytomegalovirus,HCMV)UL136基因在临床低传代分离株中的多态性,探讨其多态性与HCMV先天性感染不同致病性之间的关系。方法 对48株经荧光定量PCR方法检测HCMV DNA为阳性的临床低传代分离株进行HCMV ULl36全序列PCR扩增,对于扩增阳性的12株PCR产物进行ULl36基因全序列测定及结果分析。结果 48株临床低传代分离株ULl36 PCR扩增,12株阳性,阳性率25%,以HCMV Toledo株作为参考株,进行序列比较分析表明,12株临床分离株ULl36开放阅读框架(open reading frame,ORF)长度均与Toledo株相同,为723bp,编码241个氨基酸的蛋白。DNA序列变异均为碱基替换,不同临床分离株ULl36基因与Toledo株进行同源性比较,结果在核苷酸水平为97.7%~99.3%,氨基酸水平为96.6%~99.1%。ULl36编码蛋白的氨基酸变异率为0.83%~3.3%。二级结构预测分为两种构象。大多数HCMV ULl36蛋白翻译后修饰位点在所有分离株中均高度保守,仅几个位点在一些分离株中存在缺失或新增。Toledo株及12株临床分离株核苷酸及氨基酸序列系统进化树分析表明:45J最接近Toledo株。结论 12株临床低传代分离株HCMV ULl36基因DNA及其编码产物的氨基酸序列比较保守,但仍存在一定多态性。未发现不同临床分离株ULl36基因多态性与HCMV先天性感染的表现关系。 相似文献
33.
动态监测SARS病人IL-1α、IL-1β、TNFα和IL-6含量及其意义 总被引:1,自引:0,他引:1
目的 :动态监测SARS病人IL 1α、IL 1β、TNFα和IL 6含量并探讨其意义。方法 :采用酶联免疫吸附法定量检测早期、恢复期SARS病人以及出院后SARS随访者 ,一线未患SARS健康医护人员及健康体检者血清中IL 1α、IL 1β、TNFα和IL 6含量。结果 :IL 1α和IL 1β含量在早期、恢复期与其他组比较均显著升高 (P <0 0 5 )。SARS早期组TNFα均值显著高于其他组(P <0 0 0 5 ) ,SARS恢复期组均值显著高于SARS随访组、急诊等一线未患SARS组和健康对照组 (P <0 0 1)。SARS早期组IL 6均值显著高于其他各组 (P <0 0 0 5 ) ,SARS随访组与急诊等一线未患SARS组和健康对照组间均值比较 ,均有显著差异 (P <0 0 1)。结论 :SARS在发病过程中其病理损伤与细胞因子IL 1、TNFα和IL 6有关。 相似文献
34.
35.
A reevaluation of the duration of survival after the onset of dementia 总被引:15,自引:0,他引:15
Wolfson C Wolfson DB Asgharian M M'Lan CE Ostbye T Rockwood K Hogan DB;Clinical Progression of Dementia Study Group 《The New England journal of medicine》2001,344(15):1111-1116
BACKGROUND: Dementia shortens life expectancy; estimates of median survival after the onset of dementia have ranged from 5 to 9.3 years. Previous studies of people with existing dementia, however, may have underestimated the deleterious effects of dementia on survival by failing to consider persons with rapidly progressive illness who died before they could be included in a study (referred to as length bias). METHODS: We used data from the Canadian Study of Health and Aging to estimate survival from the onset of symptoms of dementia; the estimate was adjusted for length bias. A random sample of 10,263 subjects 65 years old or older from throughout Canada was screened for cognitive impairment. For those with dementia, we ascertained the date of onset and conducted follow-up for five years. RESULTS: We analyzed data on 821 subjects, of whom 396 had probable Alzheimer's disease, 252 had possible Alzheimer's disease, and 173 had vascular dementia. For the group as a whole, the unadjusted median survival was 6.6 years (95 percent confidence interval, 6.2 to 7.1). After adjustment for length bias, the estimated median survival was 3.3 years (95 percent confidence interval, 2.7 to 4.0). The median survival was 3.1 years for subjects with probable Alzheimer's disease, 3.5 years for subjects with possible Alzheimer's disease, and 3.3 years for subjects with vascular dementia. CONCLUSIONS: Median survival after the onset of dementia is much shorter than has previously been estimated. 相似文献
36.
Shankaran S Laptook AR Ehrenkranz RA Tyson JE McDonald SA Donovan EF Fanaroff AA Poole WK Wright LL Higgins RD Finer NN Carlo WA Duara S Oh W Cotten CM Stevenson DK Stoll BJ Lemons JA Guillet R Jobe AH;National Institute of Child Health Human Development Neonatal Research Network 《The New England journal of medicine》2005,353(15):1574-1584
37.
Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes 总被引:41,自引:0,他引:41
Ellis CN Krueger GG;Alefacept Clinical Study Group 《The New England journal of medicine》2001,345(4):248-255
BACKGROUND: Psoriatic plaques are characterized by infiltration with CD4+ CD45RO+ and CD8+ CD45RO+ memory effector T lymphocytes. The recombinant protein alefacept binds to CD2 on memory effector T lymphocytes, inhibiting their activation. METHODS: In a multicenter, randomized, placebo-controlled, double-blind study, we evaluated alefacept as a treatment for psoriasis. Two hundred twenty-nine patients with chronic psoriasis received intravenous alefacept (0.025, 0.075, or 0.150 mg per kilogram of body weight) or placebo weekly for 12 weeks, with follow-up for 12 additional weeks. Before treatment, the median scores on the psoriasis area-and-severity index were between 14 and 20 in all groups (0 denotes no psoriasis and 72 the most severe disease possible). RESULTS: Alefacept was well tolerated and nonimmunogenic. The mean reduction in the score on the psoriasis area-and-severity index two weeks after treatment was greater in the alefacept groups (38, 53, and 53 percent in the groups receiving 0.025, 0.075, and 0.150 mg per kilogram, respectively) than in the placebo group (21 percent, P<0.001). Twelve weeks after treatment, 28 patients who had received alefacept alone were clear or almost clear of psoriasis. Three patients in the placebo group were clear or almost clear; all three had received additional systemic therapy for psoriasis. Alefacept reduced peripheral-blood memory effector T-lymphocyte (CD45RO+) counts, and the reduction in the number of memory-effector T lymphocytes was correlated with the improvement in psoriasis. CONCLUSIONS: Treatment with alefacept for 12 weeks is associated with improvement in chronic plaque psoriasis; some patients have a sustained clinical response after the cessation of treatment. Alefacept selectively targets CD45RO+ memory effector T lymphocytes, suggesting that they have a role in the pathogenesis of psoriasis. 相似文献
38.
Sulkowski MS Felizarta F Smith C Slim J Berggren R Goodman R Ball L Khalili M Dieterich DT;Hepatitis Resource Network Clinical Trials Group 《Journal of acquired immune deficiency syndromes (1999)》2004,35(5):464-472
Among HIV-infected persons, chronic hepatitis C virus (HCV) infection causes substantial morbidity and mortality. However, few studies have evaluated the safety and efficacy of interferon alfa (IFN) and ribavirin (RBV) therapy in co-infected persons. Accordingly, a randomized, controlled, open-label, multicenter trial was conducted to establish the safety, tolerability, and efficacy of IFN alfa-2b 3 mIU daily plus RBV 800 mg/d compared with IFN alfa-2b 3 mIU thrice weekly (TIW) plus RBV 800 mg/d in HCV treatment-naive, HIV-infected subjects with compensated liver disease and stable HIV disease. The primary endpoint was sustained virologic response (SVR), defined as an undetectable HCV RNA level 24 weeks after discontinuation of HCV therapy. At study entry, subjects in both groups were similar with respect to age, gender, HCV genotype, and HIV disease status. Of 180 randomized subjects, 162 received at least 1 dose of study medication, constituting the modified intention-to-treat population. After 12 weeks of therapy, 122 (75%) had serum HCV RNA levels assessed; of these subjects, early virologic response (undetectable HCV RNA or >2 log10 decrease from baseline) was observed in 33 (42%) and 13 (16%) of subjects taking daily and TIW IFN, respectively (P < 0.001). SVR was observed in 15 (19.0%) and 7 (8.4%) of subjects taking daily and TIW IFN, respectively (P = 0.05). Adverse events were similar in both groups. However, while no deaths or opportunistic infections were observed, nearly 30% of subjects stopped treatment due to adverse events and 7 subjects experienced a serious adverse event. In conclusion, SVR was achieved in 19% of HIV/HCV coinfected subjects treated with daily IFN plus RBV, but the effectiveness of therapy was substantially diminished by relatively high rates of treatment-related toxicity. 相似文献
39.
本文报告了山西省92—99年细菌室间质评的鉴定情况,结果表明,肠菌科鉴定正确率为62.9%;非发酵菌鉴定正确率为54.1%;革兰氏阳性球菌鉴定正确率为77%;弧菌科鉴定正确率为61—85%。 相似文献
40.
Velocity data from tissue Doppler imaging (TDI)can provide valuable information on regional leftventricular wallmotion. Validation of TDImyocardialvelocity measurements has been carried out indirectlyfrom gray- scale M- mode images,and discrepancieshave been reported.Mc Dicken[1] and Miyatake etal[2 ]have reported the accuracy and validity of the TDIsystem using a rotating sponge model.However theoverall motion of the heart should be considered.Inthe present study,we described a new TDI… 相似文献